Sana Biotechnology Inc Dossier - Source-backed chat

Sana Biotechnology Inc

SANANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.72

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.89Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $865.2M

Enterprise Value $883.4M

Shares Outstanding 301.6M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sana Biotechnology is a high-potential, clinical-stage biopharmaceutical company advancing engineered cell therapies. The company's core value proposition lies in its proprietary hypoimmune (HIP) platform, designed to make transplanted cells invisible to the host immune system, and its in vivo CAR T platform, which enables cell-specific genetic delivery directly inside the body. With key clinical milestones for its lead candidates SC451 (type 1 diabetes) and SG293 (blood cancers) expected over the next 12 to 18 months, Sana is positioned for significant valuation inflection points. The recent strategic collaboration with the Mayo Clinic and the appointment of seasoned CFO Brian Piper reinforce its operational execution and financial discipline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$8.43

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The bear case is defined by clinical or regulatory delays, such as FDA clinical holds on the SC451 or SG293 IND filings. Additionally, if early human data reveals safety concerns (e.g., off-target toxicity or immune rejection of HIP-modified cells), the platform's viability would be severely compromised. Under this scenario, high cash burn and a shortened runway would force highly dilutive equity raises at depressed valuations.

Base CaseCentral scenario

$8.4350%

Matches the consensus mean

The base case projects steady clinical progress with SC451 and SG293 entering the clinic in late 2026. Initial safety and tolerability data confirm the viability of the HIP and fusogen platforms. The company successfully manages its cash runway into 2027 through disciplined capital allocation, strategic equity investments (such as the Mayo Clinic collaboration), and controlled ATM utilization, aligning with the consensus analyst outlook.

Bull CaseUpside scenario

$12.0030%

The bull case assumes rapid clinical validation of the HIP platform. SC451 successfully enters Phase 1 trials and demonstrates robust, insulin-independent glucose control in type 1 diabetes patients without the need for immunosuppression. Simultaneously, SG293 shows deep B-cell depletion and a favorable safety profile in early clinical trials for non-Hodgkin lymphoma. These milestones trigger substantial milestone payments, attract high-tier biopharma partnerships, and drive a significant upward re-rating of the stock.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary hypoimmune (HIP) technology has demonstrated the ability to evade immune detection, potentially enabling off-the-shelf cell therapies without immunosuppression.
In vivo CAR T platform (SG293) offers a disruptive, 'one-and-done' treatment paradigm by delivering genetic payloads directly to target cells inside the body.
Strategic collaboration with the Mayo Clinic provides clinical validation, operational expertise, and a $25 million equity investment (with an option for an additional $25 million).
Strong leadership team strengthened by the appointment of CFO Brian Piper, bringing extensive biopharma financial and M&A experience.

Key Investment Risks

High operational cash burn typical of clinical-stage biotech companies, requiring ongoing capital access and risking shareholder dilution.
Clinical development risk, as preclinical success in non-human primates may not translate to safety and efficacy in human trials.
Intense competition in the cell therapy and gene editing spaces from well-capitalized peers.

Thesis Invalidation Triggers

Failure to file INDs or obtain FDA clearance for SC451 or SG293 clinical trials in 2026.
Severe adverse safety events or lack of efficacy in early-stage clinical trials.
Inability to secure additional funding or strategic partnerships, leading to a critical cash runway shortage before key readouts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.